Dulera mometasone/Formoterol regulatory update

Merck said in its 4Q11 earnings that FDA issued a complete response letter for an sNDA for Dulera mometasone/formoterol to treat chronic obstructive pulmonary disease (COPD). The pharma said it is dis...